Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 316

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 2
Chunk 316
---
 clinical development of its product candidates and public company compliance costs. Based on current business plans, the Company believes
that the cash available as of September 30, 2025 will not fund its operations and capital requirements for 12 months after the filing
of these unaudited condensed financial statements for the period ended September 30, 2025. The Company has arranged two equity lines of
credit, one providing for the sale of up to 25,000,000 newly issued shares of Common Stock and the other providing for the purchase of
up to $17.5 million of Common Stock on the satisfaction of certain conditions. The Company has no guarantee that the conditions will be
satisfied to require the purchase of all, or any additional amount, of the ELOC funds. On February 5, 2025, the Company entered into the
SPA, with participation from a member of the Company’s Board and a single institutional investor, for the purchase and sale of (i)
127,551 shares of our common stock or common stock equivalents in lieu thereof; and (ii) February 2025 Common Warrants to purchase up
to 127,551 shares of common stock, at a combined public offering price of $39.20 per share and warrant. In connection with this offering,
the Company received net proceeds of approximately $4.2 million. Additionally, during the nine months ended September 30, 2025, the Company
received net proceeds from the exercise of the remaining Series A Preferred Warrants, the collection of subscriptions receivable and ELOC
fundings of approximately $4.2 million. Furthermore, during the nine months ended September 30, 2025, we received net proceeds from the
sales of Series D Preferred Stock of $2.6 million.

On October 14, 2025, we
entered into the Fifth Securities Purchase Agreement, pursuant to which we agree to issue and sell up to 9,750 shares of Series E Preferred
Stock for an aggregate purchase price of up to $7 million in one or more closings. On October 16, 2025, we and the requisite buyers party
to the Fifth Securities Purchase Agreement entered into Amendment No. 1 to the Securities Purchase Agreement (the “SPA Amendment”)
to add an additional Buyer (as defined in the Fifth Securities Purchase Agreement) and increase the size of the Initial Closing (as defined
in the Fifth Securities Purchase Agreement) by $500,000 to an aggregate of approximately $2.